[
    [
        {
            "time": "2018-12-05",
            "original_text": "格隆汇港股聚焦(12.5)︱融创中国前11月合同销售额突破5000亿元招商证券11月母公司净利润增23.8%至5.51亿元",
            "features": {
                "keywords": [
                    "融创中国",
                    "合同销售额",
                    "5000亿元",
                    "招商证券",
                    "净利润",
                    "增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "房地产",
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "格隆汇港股聚焦(12.5)︱融创中国前11月合同销售额突破5000亿元招商证券11月母公司净利润增23.8%至5.51亿元",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-12-04",
            "original_text": "复星医药(02196)用于肾病透析患者高磷血症的Tenapanor片获临床试验注册审评受理",
            "features": {
                "keywords": [
                    "复星医药",
                    "Tenapanor片",
                    "肾病",
                    "高磷血症",
                    "临床试验"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(02196)用于肾病透析患者高磷血症的Tenapanor片获临床试验注册审评受理",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-12-04",
            "original_text": "复星医药(600196.SH)：Tenapanor片用于终末期肾病透析患者高磷血症治疗获临床试验注册审评受理",
            "features": {
                "keywords": [
                    "复星医药",
                    "Tenapanor片",
                    "终末期肾病",
                    "高磷血症",
                    "临床试验"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(600196.SH)：Tenapanor片用于终末期肾病透析患者高磷血症治疗获临床试验注册审评受理",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-12-04",
            "original_text": "复星医药：控股子公司获药品临床试验申请受理",
            "features": {
                "keywords": [
                    "复星医药",
                    "控股子公司",
                    "药品",
                    "临床试验"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：控股子公司获药品临床试验申请受理",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-12-04",
            "original_text": "和睦家：将利用资本市场加速医院和科室建设",
            "features": {
                "keywords": [
                    "和睦家",
                    "资本市场",
                    "医院建设",
                    "科室建设"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "和睦家：将利用资本市场加速医院和科室建设",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-12-04",
            "original_text": "智通港股通持股分析|12月4日",
            "features": {
                "keywords": [
                    "智通港股通",
                    "持股分析"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "智通港股通持股分析|12月4日",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-12-04",
            "original_text": "“后复星时代”的和睦家 非公医疗仍面临多重难题",
            "features": {
                "keywords": [
                    "后复星时代",
                    "和睦家",
                    "非公医疗",
                    "难题"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "“后复星时代”的和睦家 非公医疗仍面临多重难题",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]